Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.37)
# 1,021
Out of 5,138 analysts
97
Total ratings
43.56%
Success rate
5.9%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INDV Indivior | Maintains: Buy | $35 → $48 | $32.54 | +47.51% | 3 | Jan 12, 2026 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $6 | $1.49 | +302.68% | 3 | Jan 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $7.52 | +32.98% | 4 | Jan 9, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $46 → $60 | $45.60 | +31.58% | 8 | Jan 9, 2026 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $20 | $12.61 | +58.60% | 2 | Jan 9, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $10.48 | +100.38% | 3 | Jan 9, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $1.39 | +691.37% | 4 | Jan 9, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $8.75 | +37.14% | 4 | Jan 9, 2026 | |
| OMER Omeros | Maintains: Buy | $20 → $40 | $12.01 | +233.06% | 4 | Jan 8, 2026 | |
| MIST Milestone Pharmaceuticals | Reiterates: Buy | $8 | $2.05 | +290.24% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $23.06 | +160.19% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.02 | +296.04% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.06 | +749.06% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $18 | $6.78 | +165.49% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.21 | +111.13% | 6 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.21 | +726.45% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $84.83 | +42.64% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.09 | +78.39% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.01 | +62.30% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $5.83 | +105.83% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.38 | +196.80% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.16 | +224.07% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $6.14 | +372.31% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.93 | +191.15% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.96 | +422.30% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.23 | +3,455.56% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $10.99 | +45.59% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $11.34 | +3,912.35% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $22.84 | +158.32% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $169.41 | +6.25% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.69 | +8,078.44% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $31.63 | +1.17% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.36 | +1,617,547.06% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $13.14 | +280.52% | 1 | Jul 12, 2018 |
Indivior
Jan 12, 2026
Maintains: Buy
Price Target: $35 → $48
Current: $32.54
Upside: +47.51%
Heron Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.49
Upside: +302.68%
Xeris Biopharma Holdings
Jan 9, 2026
Reiterates: Buy
Price Target: $10
Current: $7.52
Upside: +32.98%
Collegium Pharmaceutical
Jan 9, 2026
Reiterates: Buy
Price Target: $46 → $60
Current: $45.60
Upside: +31.58%
Enanta Pharmaceuticals
Jan 9, 2026
Reiterates: Buy
Price Target: $20
Current: $12.61
Upside: +58.60%
Trevi Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $21
Current: $10.48
Upside: +100.38%
Rani Therapeutics Holdings
Jan 9, 2026
Reiterates: Buy
Price Target: $11
Current: $1.39
Upside: +691.37%
Eupraxia Pharmaceuticals
Jan 9, 2026
Reiterates: Buy
Price Target: $12
Current: $8.75
Upside: +37.14%
Omeros
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $12.01
Upside: +233.06%
Milestone Pharmaceuticals
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $2.05
Upside: +290.24%
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $23.06
Upside: +160.19%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $2.02
Upside: +296.04%
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $1.06
Upside: +749.06%
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $6.78
Upside: +165.49%
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.21
Upside: +111.13%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.21
Upside: +726.45%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $84.83
Upside: +42.64%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $10.09
Upside: +78.39%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $8.01
Upside: +62.30%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $5.83
Upside: +105.83%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $4.38
Upside: +196.80%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.16
Upside: +224.07%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $6.14
Upside: +372.31%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.93
Upside: +191.15%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.96
Upside: +422.30%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.23
Upside: +3,455.56%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $10.99
Upside: +45.59%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $11.34
Upside: +3,912.35%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $22.84
Upside: +158.32%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $169.41
Upside: +6.25%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.69
Upside: +8,078.44%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $31.63
Upside: +1.17%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.36
Upside: +1,617,547.06%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $13.14
Upside: +280.52%